Von Hoff D D
Cancer Therapy and Research Center of South Texas, San Antonio.
Semin Oncol. 1991 Oct;18(5 Suppl 7):58-61.
The human tumor cloning system is an in vitro assay that has been used to predict response of patients' tumors to conventional antineoplastic agents as well as to biologic agents. In addition, the assay has been used to screen for antitumor activity of newly discovered cytotoxics and biologics. The purpose of the present series of studies was to determine whether there are combinations of interferon alfa (rIFN-alpha) and cytotoxic agents that demonstrate synergism in this in vitro assay. In these studies, there was significant synergism for doxorubicin + rIFN-alpha, fluorouracil + rIFN-alpha, and etoposide + rIFN-alpha. Synergism was noted across a wide variety of tumor types. Results from these in vitro studies suggest that selected combinations of interferon + cytotoxic agents should be tested in clinical trials.
人肿瘤克隆系统是一种体外检测方法，已被用于预测患者肿瘤对传统抗肿瘤药物以及生物制剂的反应。此外，该检测方法还被用于筛选新发现的细胞毒性药物和生物制剂的抗肿瘤活性。本系列研究的目的是确定在这种体外检测中，α干扰素（rIFN-α）与细胞毒性药物的联合使用是否具有协同作用。在这些研究中，阿霉素+rIFN-α、氟尿嘧啶+rIFN-α和依托泊苷+rIFN-α具有显著的协同作用。在多种肿瘤类型中均观察到了协同作用。这些体外研究结果表明，应在临床试验中测试干扰素与细胞毒性药物的特定联合使用。
